Gilead Sciences, Inc. (NASDAQ:GILD) will release earnings results for the second quarter, after the closing bell on Thursday, ...

The Foster City, Calif.-based biopharmaceutical company said the growth was driven by Biktarvy, Descovy, Trodelvy and ...

Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year ...

Now, let’s get to the juicy part. In a dataset that goes back to January 2019, the 4-6-U sequence has flashed 13 times on a ...

The stock's fall snapped a two-day winning streak.

This was the stock's second consecutive day of gains.

NasdaqGS:GILD 1 Year Share Price vs Fair Value Explore Gilead Sciences's Fair Values from the Community and ...

Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its ...

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed ...

Gilead Sciences Inc. (NASDAQ:GILD) is one of the most undervalued quality stocks to buy according to hedge funds. On July 25, the European Medicines Agency’s Committee for Medicinal Products for Human ...

Gilead Sciences ( NASDAQ: GILD) was upgraded to Buy from Hold at Truist after the company raised full year sales and profit ...

Fintel reports that on August 8, 2025, Truist Securities upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Hold ...